J
Jan A. Burger
Researcher at University of Texas MD Anderson Cancer Center
Publications - 543
Citations - 33028
Jan A. Burger is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 83, co-authored 511 publications receiving 28306 citations. Previous affiliations of Jan A. Burger include University of Texas Health Science Center at Houston & University of Freiburg.
Papers
More filters
Journal ArticleDOI
A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome.
Fevzi Firat Yalniz,Naval Daver,Katayoun Rezvani,Steven M. Kornblau,Maro Ohanian,Gautam Borthakur,Courtney D. DiNardo,Marina Konopleva,Jan A. Burger,Yvonne Gasior,Sherry Pierce,Hagop M. Kantarjian,Guillermo Garcia-Manero +12 more
TL;DR: Although the small sample size precludes definitive conclusions, the results of this study indicate the efficacy and safety of lirilumab in patients with myelodysplastic syndrome are indicated and the median overall survival has not yet been reached.
Journal ArticleDOI
CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates.
TL;DR: An association of CCL3 expression by CLL cells with increased numbers of CD3+ T cells and CD57+ cells in the lymph node microenvironment, which may promote CLL cell survival and proliferation is demonstrated.
Journal ArticleDOI
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure
Uri Rozovski,Ohad Benjamini,Preetesh Jain,Philip A. Thompson,William G. Wierda,Susan O'Brien,Jan A. Burger,Alessandra Ferrajoli,Stefan Faderl,Elizabeth J. Shpall,Chitra Hosing,Issa F. Khouri,Richard E. Champlin,Michael J. Keating,Zeev Estrov +14 more
TL;DR: Patients with CLL in whom allogeneic SCT fails may have a response to and benefit from salvage therapies, and their prognosis is relatively good.
Journal ArticleDOI
Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia
Elisa Ten Hacken,Mariela Sivina,Ekaterina Kim,Susan O'Brien,William G. Wierda,Alessandra Ferrajoli,Zeev Estrov,Michael J. Keating,Thomas Oellerich,Cristina Scielzo,Paolo Ghia,Federico Caligaris-Cappio,Jan A. Burger +12 more
TL;DR: Very distinct outcomes of IgM and IgD isotype activation in CLL cells are demonstrated, providing novel insight into the regulation of BCR signaling inCLL.
Journal ArticleDOI
A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation
Nitin Jain,Alessandra Ferrajoli,Sreyashi Basu,Philip A. Thompson,Jan A. Burger,Tapan M. Kadia,Zeev Estrov,Naveen Pemmaraju,Wanda Lopez,Beenu Thakral,Joseph D. Khoury,Carlos E. Bueso-Ramos,Jorge Blando,Susan O'Brien,Hagop M. Kantarjian,James P. Allison,Michael J. Keating,Padmanee Sharma,William G. Wierda +18 more
TL;DR: The combination of nivolumab and ibrutinib has clinical activity in pts with RT with a 43% response rate and Correlative studies, including flow-cytometry and immunohistochemistry for PD1 and PDL1 are ongoing.